Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects

Ann Neurol. 2017 May;81(5):749-753. doi: 10.1002/ana.24921. Epub 2017 May 4.


We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid β1-42 (≥640pg/ml) levels were related with rate of clinical progression in a sample of 393 nondemented memory clinic patients. Lower normal levels were associated with faster clinical progression, and this depended on baseline cognitive status (subjective cognitive decline: hazard ratio [HR] = 0.57, p < 0.05; mild cognitive impairment: HR = 0.19, p < .01), indicating that normal CSF amyloid levels do not exclude incident Alzheimer disease. These findings suggest that research on preclinical markers for Alzheimer disease should take the continuum of CSF amyloid β1-42 levels within the normal range into account. Ann Neurol 2017;81:749-753.

MeSH terms

  • Aged
  • Alzheimer Disease / cerebrospinal fluid*
  • Alzheimer Disease / physiopathology
  • Amyloid beta-Peptides / cerebrospinal fluid*
  • Cognitive Dysfunction / cerebrospinal fluid*
  • Cognitive Dysfunction / physiopathology
  • Disease Progression*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Memory Disorders / cerebrospinal fluid*
  • Memory Disorders / physiopathology
  • Middle Aged
  • Peptide Fragments / cerebrospinal fluid*
  • Prognosis


  • Amyloid beta-Peptides
  • Peptide Fragments
  • amyloid beta-protein (1-42)